{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:22:07Z","timestamp":1789590127678,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s10147-024-02663-4","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T15:59:35Z","timestamp":1732204775000},"page":"27-39","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9331-2210","authenticated-orcid":false,"given":"Michiyasu","family":"Murakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Iino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Akechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyo K.","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Satomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuhei","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Aogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako Eguchi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"2663_CR1","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","volume":"24","author":"B Bloechl-Daum","year":"2006","unstructured":"Bloechl-Daum B, Deuson RR, Mavros P et al (2006) Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472\u20134478. https:\/\/doi.org\/10.1200\/JCO.2006.05.6382","journal-title":"J Clin Oncol"},{"key":"2663_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","volume":"26","author":"K Aogi","year":"2021","unstructured":"Aogi K, Takeuchi H, Saeki T et al (2021) Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for antiemesis. Int J Clin Oncol 26:1\u201317. https:\/\/doi.org\/10.1007\/s10147-020-01818-3","journal-title":"Int J Clin Oncol"},{"key":"2663_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/annonc\/mdq194","volume":"21","author":"F Roila","year":"2010","unstructured":"Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Annal Oncol 21:232\u2013243. https:\/\/doi.org\/10.1093\/annonc\/mdq194","journal-title":"Annal Oncol"},{"key":"2663_CR4","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"E Basch","year":"2011","unstructured":"Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189\u20134198. https:\/\/doi.org\/10.1200\/JCO.2010.34.4614","journal-title":"J Clin Oncol"},{"key":"2663_CR5","unstructured":"National Comprehensive Cancer Network (2014) NCCN clinical practice guidelines in oncology version1: Antiemesis. Accessed 13 Sep 2014"},{"key":"2663_CR6","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/annonc\/mdw220","volume":"27","author":"K Suzuki","year":"2016","unstructured":"Suzuki K, Yamanaka T, Hashimoto H et al (2016) Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol 27:1601\u20131606. https:\/\/doi.org\/10.1093\/annonc\/mdw220","journal-title":"Ann Oncol"},{"key":"2663_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","volume":"14","author":"FP Bymaster","year":"1996","unstructured":"Bymaster FP, Calligaro DO, Falcone JF et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87\u201396. https:\/\/doi.org\/10.1016\/0893-133X(94)00129-N","journal-title":"Neuropsychopharmacology"},{"key":"2663_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/BF02245606","volume":"124","author":"A Schotte","year":"1996","unstructured":"Schotte A, Janssen PF, Gommeren W et al (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57\u201373. https:\/\/doi.org\/10.1007\/BF02245606","journal-title":"Psychopharmacology"},{"key":"2663_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/s0014-2999(00)00037-6","volume":"390","author":"FP Bymaster","year":"2000","unstructured":"Bymaster FP, Falcone JF et al (2000) Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium. Eur J Pharmacol 390:245\u2013258. https:\/\/doi.org\/10.1016\/s0014-2999(00)00037-6","journal-title":"Eur J Pharmacol"},{"key":"2663_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC et al (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-Induced nausea and vomiting:a randomized phase III trial. J Support Oncol 9:188\u2013195. https:\/\/doi.org\/10.1016\/j.suponc.2011.05.002","journal-title":"J Support Oncol"},{"key":"2663_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1756-9966-28-131","volume":"28","author":"L Tan","year":"2009","unstructured":"Tan L, Liu J, Liu X et al (2009) Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:131\u2013137. https:\/\/doi.org\/10.1186\/1756-9966-28-131","journal-title":"J Exp Clin Cancer Res"},{"key":"2663_CR12","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/ecc.12260","volume":"24","author":"J Liu","year":"2015","unstructured":"Liu J, Tan L, Zhang H et al (2015) QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist. Eur J Cancer Care 24:436\u201343. https:\/\/doi.org\/10.1111\/ecc.12260","journal-title":"Eur J Cancer Care"},{"key":"2663_CR13","first-page":"22","volume":"62","author":"DB Allison","year":"2001","unstructured":"Allison DB, Casey DE (2001) Antipsychotic induced weight gain: a review of the literature. J Clin Psychiatry 62:22\u201331","journal-title":"J Clin Psychiatry"},{"key":"2663_CR14","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0033-3182(99)71210-7","volume":"40","author":"LE Goldstein","year":"1999","unstructured":"Goldstein LE, Sporn J, Brown S et al (1999) New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 40:438\u2013443. https:\/\/doi.org\/10.1016\/S0033-3182(99)71210-7","journal-title":"Psychosomatics"},{"key":"2663_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/s0014-2999(01)01399-1","volume":"430","author":"FP Bymaster","year":"2001","unstructured":"Bymaster FP, Falcone JF, Bauzon D et al (2001) Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine. Eur J Pharmacol 430:341\u2013349. https:\/\/doi.org\/10.1016\/s0014-2999(01)01399-1","journal-title":"Eur J Pharmacol"},{"key":"2663_CR16","unstructured":"National Comprehensive Cancer Network (2017) NCCN clinical practice guidelines in oncology version1: antiemesis. Accessed 23 Mar 2017"},{"key":"2663_CR17","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2017) American Society of Clinical Oncology practice guideline update. J Clin Oncol 35:3240\u20133261. https:\/\/doi.org\/10.1200\/JCO.2017.74.4789","journal-title":"J Clin Oncol"},{"key":"2663_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(20)30014-0","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicenter, randomized, double-blind, placebo- controlled, phase 3 trial. Lancet Oncol 21:242\u2013249. https:\/\/doi.org\/10.1016\/S1470-2045(20)30014-0","journal-title":"Lancet Oncol"},{"key":"2663_CR19","volume-title":"Minds manual for Guideline 18 development","author":"N Kojimahara","year":"2017","unstructured":"Kojimahara N, Nakayama T, Morizane T et al (2017) Minds manual for Guideline 18 development. Japan Council for Quality Health Care, Tokyo"},{"key":"2663_CR20","doi-asserted-by":"publisher","first-page":"a744","DOI":"10.1136\/bmj.a744","volume":"337","author":"R Jaeschke","year":"2008","unstructured":"Jaeschke R, Guyatt GH, Dellinger P et al (2008) Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 337:a744. https:\/\/doi.org\/10.1136\/bmj.a744","journal-title":"BMJ"},{"key":"2663_CR21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ et al (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa1515725","journal-title":"N Engl J Med"},{"key":"2663_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.breast.2020.01.005","volume":"50","author":"W Yeo","year":"2020","unstructured":"Yeo W, Lau TK, Li L et al (2020) A randomized study of olanzapine-containing versus standard antiemetic regimen to prevent chemotherapy-induced nausea and vomiting in Chinese patients with breast cancer. Breast 50:30\u201338. https:\/\/doi.org\/10.1016\/j.breast.2020.01.005","journal-title":"Breast"},{"key":"2663_CR23","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","volume":"23","author":"T Yanai","year":"2018","unstructured":"Yanai T, Iwasa S, Hashimoto H et al (2018) A double-blind randomized phase II dose-finding study of Olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol 23:382\u2013388. https:\/\/doi.org\/10.1007\/s10147-017-1200-4","journal-title":"Int J Clin Oncol"},{"key":"2663_CR24","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.breast.2020.11.002","volume":"54","author":"M Clemons","year":"2020","unstructured":"Clemons M, Dranitsaris G, Sienkiewicz M et al (2020) A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at a high risk of chemotherapy-induced nausea and vomiting. Breast 54:278\u2013285. https:\/\/doi.org\/10.1016\/j.breast.2020.11.002","journal-title":"Breast"},{"key":"2663_CR25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00520-015-2829-z","volume":"24","author":"M Abe","year":"2016","unstructured":"Abe M, Hirashima Y, Kasamatsu Y et al (2016) Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Support Care Cancer 24:675\u2013682. https:\/\/doi.org\/10.1007\/s00520-015-2829-z","journal-title":"Support Care Cancer"},{"key":"2663_CR26","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/jjco\/hyw011","volume":"46","author":"J Sato","year":"2016","unstructured":"Sato J, Kashiwaba M, Komatsu H et al (2016) Effect of olanzapine for breast cancer patients resistant to triplet antiemetic therapy with nausea due to anthracycline-containing adjuvant chemotherapy. Jpn J Clin Oncol 46:415\u2013420. https:\/\/doi.org\/10.1093\/jjco\/hyw011","journal-title":"Jpn J Clin Oncol"},{"key":"2663_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2512\/jspm.8.127","volume":"8","author":"M Abe","year":"2013","unstructured":"Abe M, Komeda S, Kuji S et al (2013) Clinical research of olanzapine for prevention of chemotherapy\u2212induced nausea and vomiting resistant to standard antiemetic treatment for highly emetogenic chemotherapy. Palliative Care Res 8:127\u2013134","journal-title":"Palliative Care Res"},{"key":"2663_CR28","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/jjco\/hyx084","volume":"47","author":"K Nakashima","year":"2017","unstructured":"Nakashima K, Murakami H, Yokoyama K et al (2017) A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy. Jpn J Clin Oncol 47:840\u2013843. https:\/\/doi.org\/10.1093\/jjco\/hyx084","journal-title":"Jpn J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02663-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02663-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02663-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T06:05:32Z","timestamp":1735970732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02663-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["2663"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02663-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Michiyasu Murakami received honoraria from Taiho Pharmaceutical Co. Ltd. Kazuhisa Nakashima received honoraria from Taiho Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., AstraZeneca K.K., and Eli Lilly Japan K.K. Junichi Nishimura received honoraria from Taiho Pharmaceutical Co. Ltd. Eriko Satomi received honoraria from Shionogi & Co. Ltd. Masayuki Takeda received honoraria from Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., and Bayer. Narikazu Boku received honoraria from Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb, Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Eli Lilly Japan K.K. Koji Matsumoto received honoraria from MSD K.K., Kyowa Kirin Co., Ltd., and Chugai Pharmaceutical Co., Ltd., as well as research funding from Daiichi Sankyo Co., Ltd., MSD K.K., Gilead Sciences, Inc., and Eli Lilly Japan K.K. Nobuyuki Yamamoto received honoraria from MSD K.K., Accuray Japan K.K., AstraZeneca K.K., Abbvie Inc., Amgen Inc., Ono Pharmaceutical Co., Ltd., Guardant Health Japan Corp., Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Chugai Foundation for Innovative Drug Discovery Science, Lao Tsumura Co., Ltd., Terumo Corporation, Eli Lilly Japan K.K., Nippon Kayaku Co., Ltd., Novartis AG, Pfizer Global Supply Japan Inc., Merck Biopharma Co., Ltd, Pfizer Global Supply Japan Inc., Merck Biopharma Co., Ltd., Janssen Pharmaceutical K.K., and USACO Corporation, as well as legal fees in case of iawsuit from Taiho Pharmaceutical Co., Ltd., Boehringer Ingelheim Japan, Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Nippon Kayaku Co., Ltd., Prime Research Institute for Medical RWD, Inc., AstraZeneca K.K., and A2 Healthcare Corporation. Takako Eguchi Nakajima received research funding from KBBM, Inc. and Takeda Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Formal consent was not required for this type of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consented to the publication of this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}